Relapsed/Refractory Multiple Myeloma, DLBCL, and CLL: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner

Abstract

Oxana Megherea, PharmD, BCOP, of the Hospital of the University of Pennsylvania, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. She also summarizes a subgroup analysis of elderly patients enrolled in the phase III POLARIX study and results of a phase III study of ibrutinib, obinutuzumab, and venetoclax vs. ibrutinib plus obinutuzumab (IO) for treatment-naive older patients with chronic lymphocytic leukemia.